Inhibiting mutant IDH-1
US11376246B2 · kind B2 · utility
0Cited by
31References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 25, 2019 |
| Grant date | Jul 5, 2022 |
| Priority date | — |
| Expiry date | Nov 25, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/7068
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.